Wen Chuan Zhou
Chief Executive Officer at MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
Net worth: 726 590 $ as of 30/05/2024
Wen Chuan Zhou active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Director/Board Member | 31/12/2008 | - |
| Chief Executive Officer | 31/12/2008 | - | |
| GONGNIU GROUP CO.,LTD. | Director/Board Member | 19/05/2021 | - |
Shenzhen Wingor Bio-technology Co., Ltd.
 Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Director/Board Member | - | - |
Career history of Wen Chuan Zhou
Training of Wen Chuan Zhou
| University of British Columbia | Graduate Degree |
| The Chinese University of Hong Kong | Masters Business Admin |
Statistics
International
| Hong Kong | 3 |
| China | 3 |
| Canada | 2 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 1 |
| Masters Business Admin | 1 |
Sectoral
| Consumer Services | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Distribution Services |
| GONGNIU GROUP CO.,LTD. | Producer Manufacturing |
| Private companies | 1 |
|---|---|
Shenzhen Wingor Bio-technology Co., Ltd.
Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Commercial Services |
- Stock Market
- Insiders
- Wen Chuan Zhou
- Experience